Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Immunocore Holdings plc (IMCR)

Immunocore reaches target enrollment of 540 patients in Phase 3 TEBE-AM melanoma trial

Neutral Impact 3 of 5 product/contract Written later

Immunocore said it has reached its target enrollment of 540 patients in the registrational Phase 3 TEBE-AM trial of KIMMTRAK (tebentafusp) in previously treated advanced melanoma. Patients already in the trial will continue to be followed for the planned overall survival analysis, and the company expects to share topline data as early as the end of 2026.

Key points

  • Target enrollment of 540 patients in the TEBE-AM trial was achieved, as announced September 14, 2026.
  • The primary endpoint of the trial is overall survival.
  • The company believes tebentafusp could address up to 4,000 HLA-A*02:01-positive patients in the US and Europe in the post-PD1 setting.
  • Topline data are expected as early as the end of 2026.

The filing

CompanyImmunocore Holdings plc (IMCR)
Form8-K, current report
Filed with the SECSep 14, 2026, 7:15 AM ET
Accession number0001671927-26-000026

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.